Nyxoah shares surge 12.47% premarket as CMS boosts Medicare reimbursement for Genio therapy under 2026 rule.

Nyxoah surged 12.47% in premarket trading following the U.S. Centers for Medicare & Medicaid Services (CMS) finalization of the CY2026 reimbursement rule, which significantly increased Medicare payments for its Genio® hypoglossal nerve stimulation therapy. The CMS assigned CPT Code 64568—used for Genio implants—to New Technology APC 1580, boosting hospital outpatient reimbursement by 48% to $45,000 and ASC facility reimbursement by 58% to $42,373, effective January 1, 2026. This decision strengthens the economic viability of Genio’s adoption, particularly in Medicare-heavy institutions, and aligns with Nyxoah’s U.S. commercialization strategy. The company also highlighted $77 million in funding to scale commercialization efforts, further reinforcing investor confidence in the therapy’s market potential.